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Background: Inventory control practices for adult vaccines, specifically Shingrix, in ambulatory 
clinics are not well known or researched. This quality improvement project takes place at a small 
healthcare organization consisting of a hospital and thirteen ambulatory clinics in Northern New 
England. Seven of the thirteen clinics have the Shingrix vaccine in their inventory. 
Purpose: The aim of this quality improvement project was multifaceted. The first matter was the 
establishment of a two-week PAR level at seven of the thirteen ambulatory clinics connected to 
the organization. The second was the design and implementation of a Shingrix vaccine 
management program for seven of the thirteen ambulatory clinics. This included the 
redistribution of inventory to prevent loss. Lastly, to create an inventory management education 
program for our clinical staff. 
Methods: A rapid review of the literature was conducted using an ELCLIPS format using the 
Business Source Ultimate database. An informal framework of LEAN was used for this project. 
Three months of baseline inventory evidence was collected (pre-COVID-19) and clinic PAR 
levels were established from an uncertain baseline inventory and use volume estimate. 
Interventions:  A manual inventory count was conducted at each clinic. Purchase and billing 
information was compared to the manual count obtained at each site. Two-week PAR levels 
were established by comparing use tallies to a three-month use rate (pre-COVID-19). These 
figures were extracted from the electronic health record. An educational plan for clinic 
employees was developed and personnel from each of the seven clinics participated.  
Results: Seven months following the onset of the project’s implementation there were no 
recorded Shingrix vaccine losses and the administration of Shingrix vaccine has increased. 





Significant gaps in the literature regarding inventory management and ambulatory clinics were 
exposed. This quality improvement project ascertained evidence demonstrating a cost savings 
was obtained through improved Shingrix vaccine inventory management.  
Conclusions: There are opportunities to improve Shingrix vaccine inventory management at the 
organization’s seven ambulatory clinics. The processes developed for this project are easily 
replicated and sustainable. Stakeholders within the organization have deemed this project 
financially beneficial to the organization and to the community: therefore, it has become a 
foundation for inventory management at our thirteen clinic sites. 
Keywords: outpatient and ambulatory clinics, inventory, supply chain management, cost 
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A Quality Improvement Initiative to Manage Shingrix Vaccine Inventory in Ambulatory Clinics 
Introduction 
According to the American Hospital Association, the COVID-19 pandemic has 
challenged healthcare organizations with unprecedented and unforeseen financial implications 
(American Hospital Association, 2020). The National Rural Health Association reports a crucial 
action in response to the COVID-19 crisis any healthcare organization can take is to keep a close 
eye on expenses in order to maintain essential supplies (Birk, 2020). Vaccines are essential 
supplies. Vaccines such as Shingrix can protect against shingles, which is a very painful and 
costly disease. The Centers for Disease Control and Prevention (CDC) estimates one out of every 
three people in the United States will develop shingles because of a previous infection commonly 
known as chicken pox (CDC, 2019).  
Problem Description 
  Herpes zoster, also known as shingles, is caused by the reactivation of the varicella-
zoster virus (VZV), the same virus that causes varicella (chickenpox). Reactivation of VZV that 
has remained dormant within dorsal root ganglia, often for decades after the patient’s initial 
exposure to the virus in the form of varicella (chickenpox), results in herpes zoster (shingles). 
While usually a self-limited rash with pain, it can be far more serious as acute cases often lead to 
post herpetic neuralgia (PHN) and is responsible for a significant economic burden. 
 Shingrix, is an FDA approved vaccine for the prevention of herpes zoster (shingles) in 
adults aged 50 years and older. According to the manufacturer GSK, Shingrix is 90% effective at 
preventing the reactivation of herpes zoster in adults (GSK, 2020). At one time, the demand for 
the vaccine exceeded the supply and the drug was placed on long-term backorder.  





In October 2019, the clinics began overcome Shingrix vaccine shortages by establishing 
individual GSK accounts and enrolling in the manufacturer’s auto shipment program. 
Establishing an account with the manufacturer ensured an allocation of 10 doses of Shingrix 
every three-four weeks to each clinic as opposed to 10 doses every three-four week to the 
organization for distribution across the seven sites. The enrollment in GSK drop shipping 
program resulted in a 700% increase in inventory. The vaccine was drop shipped from the 
manufacturer to each clinic at a cost of $186.41 per vial. Direct shipping to each clinic continued 
through January 2020.  
In late 2019 and early 2020, large volumes of Shingrix were discovered in the 
refrigerators of the seven ambulatory clinics targeted for this project amounting to thousands of 
dollars of inventory with some of the Shingrix vials nearing their expiration dates. Identification 
of this surplus in tandem with lack of inventory management resulted in this targeted area for 
process improvement. 
There was neither a formal nor an informal process for vaccine inventory management at 
the ambulatory clinics. The areas of quality improvement for the clinics were to establish two-
week PAR levels for the Shingrix vaccine and to create an inventory management education 
program for the clinical staff at the seven ambulatory clinic sites administering the Shingrix 
vaccine. 
Initially, the scope of this project was to develop an inventory management program by 
establishing two-week PAR levels and for all vaccines at all thirteen ambulatory clinics. As the 
COVID-19 pandemic unfolded, several constraints arose. Unforeseen disruptions in healthcare 





services resulted a paradigm shift in the delivery of care and in a project realignment. The focus 
changed to only Shingrix vaccine management.   
Shingrix vaccine inventory management became this project’s target because it was 
thought to be the most impactful vaccine in regard to inventory management issues. 
Administering the Shingrix vaccine as opposed to it sitting in clinic refrigerators would benefit 
the organization financially and support the communities this healthcare organization serves 
(U.S. Department of Health & Human Services, 2020). Creating inventory management 
standards for the Shingrix vaccine laid a solid foundation and provided a framework for the 
establishment of vaccine management across all of the thirteen ambulatory clinics.  
Available Knowledge  
There were significant gaps in the literature to describe and or support vaccine 
management in ambulatory clinics.  However, at the onset of this project, the costs realized by 
this healthcare organization having Shingrix vaccine sedentary in the refrigerators equated to 
thousands of dollars in inventory (Appendix A). Because there was no prior tracking of 
inventory, previous loss estimates are only approximate as results were self-reported to this team. 
This team became aware of four doses of Shingrix expiring prior to the onset of this project. 
Additional losses and costs are innumerable to those persons afflicted with the disease shingles, 
some of which may last a lifetime.   
Vaccines do not just prevent or minimize disease. There are both societal and 
organizational economic values to vaccination. The strength and vigor of a community’s 
population is tied to the growth and sustainability of a community’s healthcare system (Toumi & 
Ricciardi, 2015). Herpes zoster infections vacillate in severity and duration and have the 





potential to inflict a significant financial blow to its victim (Wingate, Stubbs, Ahmed, Mayaka, 
Maneno, Ettienne, Elekwachi & Clarke-Tasker, 2018). In 2015, outpatient costs for 
complications such as herpetic neuralgia estimates put the incurred costs, including medical and 
employment loss, at $2.4 billion dollars for American citizens (Harvey, Prosser, Rose, Ortega-
Sanchez & Harpaz, 2020).  
Vaccines do prevent disease. In this case, the disease shingles is 90% preventable by 
receiving the Shingrix vaccine two-dose series (GSK, 2020). While 30% of the American 
population will be afflicted with reactivation of the varicella virus (chicken pox) resulting in a 
herpes zoster (HZ) outbreak, 10% of those persons will go onto to develop post herpetic 
neuralgia (PHN). A hallmark of shingles rash is moderate to severe pain. PHN is a longer lasting 
pain syndrome from resulting nerve damage caused by the virus (Friesen, Chateau, Falk, Alessi-
Severini & Budgen, 2017).  If one were to develop a shingles infection, having had the Shingrix 
vaccination will minimize the disease effects (CDC, 2019).  
Rationale  
An informal framework of LEAN methodology was implemented to drive this quality 
improvement project. Principles of LEAN management have been successfully employed by 
healthcare organizations for decades. A team from the Massachusetts Institute of Technology 
International Motor Vehicle Program created the term “Lean” to explain Toyota’s business 
process (Simon & Canacari, 2012). This method sets forth a process to identify problems, 
analyze the root cause of issues, develop and implement solutions and evaluate outcomes. Value 
is realized by eliminating waste and consequently quality, cost and timeliness of services can be 
improved using this methodology.  





A key component of LEAN this team used is known as Gemba, a Japanese word meaning 
where the work occurs (Simon & Canacari, 2012). In the case of this healthcare organization, the 
work occurs in ambulatory clinics and that is where this team went to develop the standards for 
PAR levels, inventory management and to provide education. Supply chain management and 
operational inventory levels of Shingrix vaccine have been determined by implementing PAR 
levels. 
PAR levels help to balance inventory needs with service needs by using ratios to 
determine what the inventory needs are without compromising customer service (Wilson, Hodge 
& Bivens 2015). The establishment of PAR levels is a well-known means of minimizing 
expenses. Par level management is used in healthcare to keep enough inventory on hand to meet 
the organization and patient needs yet not exceed a predetermined amount or PAR level thus 
preventing excessive inventory and expense (Walker, 2019). Seven ambulatory clinic sites have 
used PAR levels to demonstrate that the establishment and management of PAR levels using a 
formula of a two-week usage of Shingrix vaccine +1 resulted in a cost reduction.  
Specific Aims   
The aim of this quality improvement project is multi-faceted. The first being, the 
establishment of two-week PAR levels at seven ambulatory clinics for Shingrix vaccine 
management; to implement a successful cost reduction Shingrix vaccine program in seven 
ambulatory clinics that included the redistribution of inventory; and to create an inventory 
management education program with specific training for the clinical staff. Cost reduction 
measures and resource stewardship are of particular importance in a COVID-19 world and has 
underscored the value of this project (Birk, 2020). 





• There were significant limitations with obtaining baseline data because prior to the 
development of this project as Shingrix vaccine volumes were not previously tracked or 
monitored.  
• Inventory sharing and redistribution has occurred because of accurate eCW inventory.  
o Shingrix inventory nearing expiration, within one month of expiration will be 
redistributed to another clinic for administration thus preventing expiration of 
product. 
o Alternatively, eCW eligible patient reports may be run enabling outreach to 
patients who are due or coming due for the vaccine. 
•  A two-week PAR level program to manage Shingrix inventory was developed by July 1, 
2020. 
• A clinical staff eCW training program was developed and implemented by August 1, 
2020. 
• Those persons who received eCW inventory training have become responsible for 
training the remainder of the clinical staff and new employees. 
Methods 
Context  
The setting is a small healthcare organization in New England consisting of a hospital 
and thirteen ambulatory care clinics seven of which administer adult vaccines. At the onset of the 
project, five of the seven clinics had large amounts of the Shingrix vaccine in stock. Although 
there is not an exact figure, there were hundreds of doses in inventory. During this time, the 
Shingrix vaccine was nationally backordered and there were shortages across America. This 





quality improvement project occurs during the pandemic, COVID-19. In order for healthcare 
operations to remain successful and cost efficient, waste elimination is key in supporting the 
success of the organization (Xu, et al., 2011).  Rural hospitals and healthcare organizations have  
been hit particularly hard by the COVID-19 pandemic (Khullar, Bond & Schpero, 2020). These 
factors have only strengthened the importance of this project. 
Cost Benefit Analysis   
Shingrix supply chain management was evaluated across the organization. There are 
three cost analysis associated with this quality improvement project. The first is the cost incurred 
by the ambulatory clinics and to the organization by having an abundance of the Shingrix 
vaccine sitting in refrigerators. This is inventory that has been ordered and paid for yet has not 
been administered therefore the clinic is unable to bill for the vaccine or the cost of the vaccines’ 
administration. In 2019, the cost of Shingrix was $186.41 per vial/dose. While the cost has 
decreased, it remains significant at $136.50 per vial/dose. 
The second aspect of cost analysis for this project became apparent within the first week 
of the projects implementation when the team discovered that eight vials of Shingrix would soon 
expire. The cost of these eight doses expiring could have resulted in a loss of $1,491.28 to the 
clinic but instead resulted in a profit of $ 2,912.00. The loss of these doses due to product 
expiration may also have resulted in disease. There is no way to predict the outcome of that 
possibility. Because this team recognized the doses were approaching the end of viability, the 
Shingrix vaccine was transported to another clinic and administered to patients before their 
expiration date.  





This team was also able to redistribute 80 of 100 vials being stored in one clinic to 
another site for administration. In terms of cost, this equates to nearly $15,000.00 of inventory 
sitting idle in a clinic refrigerator during a time when Shingrix was nationally backorder and 
shortages abound.  Reports were run in eCW to identify patients who were due or coming due for 
Shingrix vaccination and concurrently, Shingrix was included in pre-visit planning for upcoming 
scheduled office visits. These actions thereby shrunk the Shingrix inventory of the clinic with 
100 original stagnate doses to an inventory of 10 doses.  The two-week PAR level for this 
ambulatory clinic is currently at 20 vials.  
The third cost analysis is the cost of disease prevention and long-term complications to 
persons in the community. The CDC estimates that one out three persons in the U.S. will 
developed shingles and of those 10% to 18% will go on to develop post herpetic pain neuralgia 
(PHN) (CDC, 2019). 
In 2018, outpatient disease cost estimates for non-complicated disease cases ranged from 
$800 to $1,500 per patient.  For those developing PHN outpatient cases can range from $1,425 to 
$7,300 per patient. Productivity and work loss estimate for a non-complicated diseased person 
averages $2,350 with total societal burden for all severity levels ranging from $1 billion to $1.9 
billion (Wingate, et al., 2018) (Appendix A). 
Interventions 
In order to establish PAR levels, the team determined what data would be collected. A 
process for data extraction was developed and implemented. The process consisted of using eCW 
reporting to perform a three-month look back at Shingrix administration per site- pre-COVID-19 
and comparing that volume with purchasing orders for the same time period in conjunction with 





using the PharmacyKeeper program to track PAR levels at each site. Again, prior to this project, 
Shingrix inventory, ordering and use was not tracked. This resulted in very little baseline data to 
facilitate the process. PAR level inspection templates were designed for use with the 
PharmacyKeeper program (Appendix B). Templates for vaccine ordering were designed and 
implemented at the seven clinics (Appendix C). Policies for Vaccine Management and Standing 
Orders for Shingrix administration were written by the team and approved by the organization’s 
stakeholders (Appendix D & E). Clinic staff were educated regarding form location and use, 
policies were reviewed, and PAR levels were set. Vaccine ordering forms were placed on the 
organization’s Intranet for quick and easy access. An educational program demonstrating eCW 
inventory use was implemented (Appendix F). Review of how withdraw Shingrix from the eCW 
inventory document vaccine administration in the clinical note was conducted at seven 
ambulatory clinics sites (Appendix G). A standing order for Shingrix administration was also 
rolled out to the seven practices for use by medical assistants and nurses (Appendix H). 
Study of Interventions 
The impact of the interventions was assessed in real time in conjunction with the 
organization’s pharmacy purchasing department. In order to ensure PAR level adherence, the 
clinicians and practice managers at the seven sites will be provided with their Shingrix PAR 
levels. Whenever an ambulatory care clinic places a vaccine order to replenish their stock, the 
request is forwarded to the team for review. The team assesses several factors including if the 
correct ordering form was used, if the requested vaccine volume is in accordance with the 
established PAR level, is the current inventory in eCW accurate and if there a stagnant supply at 
one of the clinics that could be redistributed. If anything is incongruent with the recommended 





process, the team will contact the ordering clinician to discuss and educate so corrections can be 
made. Then the ordering form is returned to the pharmacy purchasing department for processing. 
Measures 
The processes are measured through onsite team inspections using the PharmacyKeeper 
program and comparing them to eCW inventory. Inventory was continually assessed via eCW to 
serve as back up for onsite inventory management. A vaccine manager at each site is responsible 
for conducting weekly inventory reconciliation between the actual inventory on hand and the 
eCW inventory. This ensures both accuracy of PAR levels and waste avoidance. If a Shingrix 
vaccine is nearing its expiration date, the team is notified. PAR levels and inventory at other 
clinics is evaluated to determine which ambulatory clinic is experiencing higher vaccine 
administration rates and redistribution of the Shingrix vaccine to the higher use clinic has 
occurred.    
Additional ongoing assessment and evaluation will include: 
• The volume of Shingrix redistribution that is occurring. This has resulted in re-evaluation 
of PAR levels for three ambulatory clinic sites. 
•  Adherence to project components based on inventory evaluation and email of Shingrix 
order requests from the pharmacy supply department to this team. 
• Tracking of all clinical staff trained and incorporating the training into onboarding of new 
clinical staff. 
• Quarterly updates on project status to Quality Department and Pharmacy Director. 
• Monthly status updates to Practice Managers. 
• Timing of implementing other vaccines into the project. 





Analysis   
The analysis of this quality improvement project is quantitative. Initially and 
unexpectedly, loss prevention occurred during an on-site inventory analysis. It was discovered 
there were eight doses of Shingrix near their expiration date. The eight doses were redistributed 
to another clinic and administered prior to their expiration. It is the hope of this project team to 
prevent Shingrix from nearing its expiration date through implementation of weekly inventory 
reconciliation and close evaluation of volumes. Usage reports continue to be extracted from 
eCW. This continues to allow the team to act quickly to redistribute vaccine from an office with 
low usage and stagnate inventory to an office with high usage and or a patient wait list for 
Shingrix vaccine. The ambulatory clinics are currently experiencing unexpected staff 
absenteeism because of COVID-19 and high employment turnover rates. This has resulted in 
much of this project oversite occurring by the team as opposed to clinical staff on site. This 
process is in current use. Since the initial redistribution of Shingrix there has been no Shingrix 
vaccine loss reported or recorded. 
Ethical Considerations   
There were no ethical considerations as this is a quality improvement project related to 
inventory control and education of clinical staff and not a patient population. There were no 
potential conflicts of interests. 
Results 
The scope of this project changed significantly because of COVID-19. Initially the range 
of this project was to include an inventory management program for all vaccines at the thirteen 
ambulatory clinics. As the COVID-19 pandemic unfolded, several constraints arose. Unforeseen 
disruptions in healthcare services resulted in a project realignment and the focus changed to only 





that of the Shingrix vaccine management. Shingrix vaccine inventory management became the 
target because it was thought to be the most impactful vaccine in regard to inventory 
management. 
The first segment of this quality improvement project was to establish a relationship with 
the pharmacy personnel including the Director and Buyer. This is the early development of our 
team. The team met weekly for several weeks with a PharmacyKeeper project developer to assist 
the team with our projects vision and needs including program user training and education. The 
PharmacyKeeper program has proven to be a useful tool for inventory management and tracking. 
A great deal of collaboration occurred between the project team and the staff of the ambulatory 
clinics. Through eCW reporting data extraction from the seven sites began. The team determined 
the inventory in eCW was not accurate at any of the seven clinics. After onsite inventory data 
was collected and purchase order information was compared two-week PAR levels were 
established for each of the clinics. A literature review was also conducted and revealed 
significant gaps in information and research to help facilitate this projects plan formation. 
Our team forged ahead to the second stage and regular meetings were planned with 
designated clinical staff at each clinic site. On occasion the meetings occurred daily because that 
level of collaboration was required to solidify the foundation at each clinic site. Clinics with 
excessive PAR levels worked with the team to redistribute Shingrix to clinics with known higher 
usage. PAR levels were re-evaluated on at least a weekly basis for all seven ambulatory clinics. 
Eight doses of soon to expire Shingrix vaccine were discovered in a clinic and the inventory was 
salvaged resulting in a cost savings from loss prevention as well as a profit from administration 
of the vaccine. 





The last stage of the project rollout mainly consisted of re-evaluation of the project’s 
implementation and plan revisions at each clinic site. The project team held regular Zoom 
meetings where project information was disseminated to each of the clinics and to the 
organization stakeholders. Modification of PAR levels occurred in real time as not leave a clinic 
without necessary Shingrix vaccine for their patients or risk loss due to expiration of the product. 
Modification of PAR levels occurred at all sites due to a surge in office visits during the summer 
once COVID-19 stress began to ease.  
Site inspections continue to occur regularly to ensure eCW inventory is accurate in that 
the numbers align with the actual inventory on hand. Education of our processes and policies 
transpired simultaneously with the clinical staff during the onsite inventory checks. Interventions 
to alter PAR levels and staff education continue at each clinic.  
An unanticipated outcome occurred at one of the ambulatory clinics. The clinical staff 
using tools put in place by this team, took it upon themselves to run reports in eCW to identify 
those patients due or coming due for either a first or second Shingrix vaccination. Patient 
outreach occurred which often resulted in a curbside nurse visit being scheduled (Appendix J). 
These actions generated revenue and provided added disease protection to patients in our 
community. The Shingrix vaccine is billed to insurance between $266.00 to $ 364.00 depending 





Shingrix  organization bills at $266.00  – our 
vaccine cost  $136.50 = 
                              $ 129. 50 
Admin fee              $ 43.00______ 
                                $172.50 per injection 







 Quality improvement projects are a healthcare organization priority, and this project was 
and remains a team effort. While there were multiple iterations of this project, COVID-19 
created the biggest obstacle and was the sole reason the team was required to pivot from a broad 
all-encompassing vaccine management project to that of a single aspect of PAR level inventory 
management for the Shingrix vaccine.  
The first aim, to develop two-week PAR levels of Shingrix vaccine at seven ambulatory 
clinics was achieved and has been re-evaluated and revised several times at three clinics because 
of alternations in patient volume. One of the alterations became necessary because a provider re-
located to another clinic and two alternations in volumes occurred at two other clinics because of 
an uptick in demand thought to be in part brought on by COVID-19 and a national promotion of 
vaccinations in general.  
The second aim, developing and implementing a cost reduction Shingrix vaccine program 
at seven ambulatory clinics is thought to be successful. However, because of a previously non-
existent inventory management program and very limited baseline data, assigning a number or 
dollar figure was not possible. We do know for certain that our supply chain management now 
better ensures that Shingrix vaccines are not lost due to things like temperature excursions and 
inventory expiration and that our volumes are in better alignment with patient need and demand.   
The third aim, developing and implementing a comprehensive vaccine inventory manage 
program has been implemented across the seven ambulatory clinics. Education with our clinical 
staff along with both onsite and remote PAR level inventory management monitoring continues 
in conjunction with the pharmacy buyer and personnel in the clinics.  






 This quality improvement project encountered several limitations the most profound an 
unanticipated was that it occurred during a pandemic. Because there was a complete lack of a 
standard approach to inventory management there was limited baseline data available and the 
team was unable to with certainty calculate wasted doses or unpaid claims data.  
At least two barriers arose concerning clinic staff of the seven clinics. One being the 
volume of staff turnover (those leaving their clinical positions) and staffing shortages and two, 
the attitude of some staff member’s attitude regarding a change in, “the way we’ve always done 
things.” This was especially challenging to address because it was important to balance enforcing 
behavioral expectations with the need to keep bodies to renew prescriptions, room patients and 
administer vaccines. There was fear that if behavior was forced to be corrected- either formally 
or informally, that the employee may just seek employment elsewhere. This balance was difficult 
but not insurmountable. It required more effort and finesse, and our time could have been better 
spent elsewhere.  
COVID-19 proved to be a limitation in that it was difficult to use previous office visit 
volumes to assist in PAR level predictions (see Table 1). Additionally, the outlier clinic 3 
acquired a provider and the provider’s panel during this period, which skewed our estimates. 
 
 
Clinic site Office Visit Volume March 
2019- October 2019 
Office Visit Volume March 
2020- October 2020 
1 NJ 14,270 11,776 
2 TA 4,756 4,023 
3 PS 2,738 4,023 
4 SE 3,648 2,817 
5 SC 14,641 13,006 
6 DY 10,727 9,125 
7 DP 7,132 5,772 
Table 1 






Another limitation of the project is the use of an antiquated pharmacy purchase tracking 
system. This made data extraction especially difficult as it was a manual process. Purchase 
orders and invoices are stored in folders on a public drive, in monthly folders per site and in 
different formats. Some of the data is available in an Excel spreadsheet while other data is the 
actual manufacturer invoice scanned into a folder as a PDF. 
Conclusions 
 This quality improvement project was also a process improvement project and was 
beneficial in terms of improving the quality of care for patients, but also generating revenue and 
prevented inventory loss all while working to unit our practices drawing personnel out of their 
silos. Shingrix management is a critical service and should not create a financial burden for 
ambulatory clinics. This team has shared and brought awareness to our clinical staff gaining 
understanding of the financial aspects of immunization, including ordering, storage 
administering, and documenting Shingrix vaccine so that these seven clinics can continue their 
mission of helping patients stay healthy while sustaining profits for the clinics.  
This project is a worthwhile endeavor. Better and more efficient methods of tracking 
Shingrix vaccines have led to a decrease in the time required by clinical staff to figure out how to 
manage inventory on their own and has prevented vaccine waste. This is a sustainable and 
replicable project with demonstrated cost savings.  
The next steps of project advancement will be to use the established framework for 
Shingrix management across thirteen ambulatory clinics for all inventory including vaccines for 
adults and children and medications. All aspects of inventory management for these clinics will 





directly and indirectly enhance patient quality of life and help to sustain the strength and vigor of 
this small community health care system. 
Sharing this project and its framework across all clinics will unify practices via inventory 
management education. While each clinic once ordered supplies and suffered in silence when 
found with either an abundance of inventory or not enough to meet the needs of the patients, we 
have now created a true fabric of collaboration. These silos have been breached through use of 
eCW and through the sharing of supplies, expenses and profits. Where once each clinic had to 
order a box of 10 Rotateq or Varicella, now this team and the clinics staff at each site will help 
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Dashboard Pharmacykeeper Inspection Completed/ Inspection History/ Scheduled Inspection for PAR Levels and Inventory 
XXXX Family Practice 
 
Scheduled Inspection Details 
Location: XXXX Family Practice 
Status: Completed 
Scheduled Inspection Date: 09/01/2020 
Actual Inspection Date: 09/14/2020 
Assigned To: Tracy Colburn 
Performed By: Tracy Colburn 
 
NOTES: You may return excessive vaccine to pharmacy attn. Sara. I will check with other offices to see what we can re-
distribute/re-locate. Thank you. 
 
Medication/Vaccine PAR Amount on Hand Return 












Vaccine Order Form 
 
 















ADULT VACCINE ORDER FORM 
 
Adult Vaccines Alt. Names Package Size Quantity 
Hep A Havrix 10 per package  
Hep B Energix B 10 per package 
 
Hep A & B Twinrix 10 per package 
 
HPV Gardasil 9 10 per package 
 
Meningococcal (A, C, W & Y) MCV 4 5 per package 
 
Meningococcal Grp B Bexsero Individual /10 per pack 
 









Prevnar 13 (Conjugate) 
 





10 per package 
 
Rabies Rabavert Individual doses  
Shingles Shringrix 10 per package   
Tdap Boostrix 
Individual/10 per pack  
Td Tetanus & Diphtheria 
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Policy: Vaccine Inventory Management and Reconciliation 
PURPOSE: 
This process is intended to promote and ensure that private and state vaccine and medication 
inventory management for both adult and children's supply is consistent, occurs on a regular 
basis, and that collaboration occurs amongst clinics. 
POLICY: 
 It is essential to any medication and vaccine program that the inventory on hand is accurate and 
accounted for in a timely manner. Good stewardship of vaccines and medications reduce waste 
and resources of all clinics and ensures documentation in eCW and ImmPact is both accurate and 
timely. Medication and vaccine inventory and reconciliation for both private and state vaccine 
will occur at the end of a day or prior to the start of a day every week. 
RESPONSIBILITY: 
All clinical staff; Practice Managers are responsible to account for this being done on a weekly 
basis; The Director of Practice Operations will designate a clinical representative to conduct 
random site audits. 
Definitions: 
Inventory: the physical supply of medication and vaccine on hand at a point in time. 
Reconciliation: the process by which one ensures all inventory is accurately accounted for and 
documented utilizing par levels and inventory logs. 
PROCEDURES: 
1. Inventory will be manually counted and recorded once per week. This process will include 
ensuring lot numbers and expiration dates are congruent with the actual inventory volume and set 
par levels are being adhered to. 
• If there is an abundance of inventory and or expiration dates are coming due in the next 
month (or two) an attempt to re-purpose the vaccine within the organization should occur.  
• Depending on the source of the medication and vaccine, options may include:  
• An email to all Practice Managers notifying of the availability of soon to 
expire inventory and asking if another office could use the inventory  
• Sending it back to the  Pharmacy (if non-VFC supply)  
• Contacting ImmPact Help Desk and requesting vaccine be posted on their 
website in hopes another practice outside of our organization can use the 
product ( if it is a VFC/State product)  





• Inventory Reports should be run from eCW and ImmPact-if applicable. If participating 
with the VFC program, reports from eCW and ImmPact should be reconciled. For 
medications and private vaccine (adult or child) inventory should be reconciled using 
eCW inventory reports.  
2. Reconciliation will occur minimally once per week when inventory is counted. 
• Reconciliation may occur in different ways depending upon what the inventory 
discrepancy is.  
• Depending on the source of missing medication or vaccine- private or State, 
options may include:  
• Running reports in eCW and cross checking to ensure documentation is 
done correctly  
• Reviewing the daily schedule to identify flags  
REFERENCES: 
























Policy: Vaccine Ordering and Delivery 
PURPOSE: 
To establish a standardized process for the ordering and delivery of vaccines from the Pharmacy 
to our clinics. To provide a reference tool for all clinics regarding the availability of vaccines that 
can and should be administered within the primary care setting. 
POLICY STATEMENT: 
It is the policy that  all Primary Care Practices will have a vaccine inventory on site for adults 
and children above and beyond those vaccines supplied through the State of Maine Vaccine For 
Children (VFC) program. Primary Care Practices will administer most necessary and standard 
vaccines and Mantoux tuberculin tests or purified protein derivative (PPD) to patients in a 
timely, efficient and convenient manner. 
RESPONSIBILITY: 
It is the responsibility of all practice personnel and clinical support staff to provide care in 
compliance with this policy. 
PROCEDURE: 
1. All vaccine ordering and delivery will utilize the Pharmacy Vaccine ordering form that is 
available on the Approved Form section on the Intranet.  
2. The ordering practice will send the completed order form via email addressed to Pharm 
Req.  
3. This same form will also serve as verification of receipt of the order and is to be 
presented by the delivery person to receiving person to ensure accuracy of order, 
accountability for accepting the order and ensuring proper refrigeration upon arrival. The 
signed form is returned to the Pharmacy by the delivery person and recorded at the 
pharmacy.  
4. Most vaccine is available to any practice location within 24 hours of ordering.  
5. Clinics are expected to manage their inventories responsibly including not having 
excessive amounts of vaccines on site, rotating stock, monitoring expiration dates and 
reaching out to other practices when expiration dates are nearing to decrease the 
occurrence of preventable vaccine wastage.  
6. Mantoux/PPD skin tests may be planted by a MA but must be read by licensed personnel 
such as a RN, LPN or provider.  
7. Vaccine refrigerators are to be consistently monitored to maintain temperatures between 
36 to 46 degrees F or 2 to 8 degrees C, freezers are to maintain temperatures between -58 
to +5 degrees F or -50 to -15 degrees C.  






Vaccines Storage and Handling Toolkit | CDC 
https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html 
































Adding Vaccine into eCW Inventory 
 



















Manually enter information in boxes and select OK. 
 
 
Shingrix has been successfully added to eCW Inventory 
 












Documentation of Administration 
In the Progress Note  
 
 






































Shingrix Standing Order 
PURPOSE: 
To reduce morbidity and mortality from herpes zoster infection (shingles) by vaccinating all 
adults who meet the criteria established by the Centers for Disease Control and Prevention's 
Advisory Committee on Immunization Practices. 
POLICY: 
Where allowed by state law, standing orders enable eligible nurses and other health care 
professionals (e.g., pharmacists) to assess the need for vaccination and to vaccinate adults who 
meet any of the criteria below. 
RESPONSIBILITY: 
It is the responsibility of ALL practice providers and clinical support staff to provide care in 
compliance with this policy. 
PROCEDURE: 
1. Assess adults age 50 Years and older for need of vaccination against herpes zoster virus 
infection. The CDC recommends two Intramuscular doses of Shingrix 2 to 6 months 
apart. It is preferred over Zostavax and should be given to any patient 50 years of age or 
older. Shingrix is appropriate for administration:  
• Whether or not they report a prior episode of herpes zoster  
• Whether or not they report a prior dose of Zostavax  
• For those with chronic medical conditions (e.g., chronic renal failure, diabetes 
mellitus, rheumatoid arthritis, chronic pulmonary disease), unless a 
contraindication or precaution exists.  
• Similar to Zostavax, Shingrix may be used for adults who:  
• Are taking low-dose immunosuppressive therapy as this may decrease the 
efficacy  
• Are anticipating immunosuppression  
• Have recovered from an immunocompromising illness  
• Are receiving other adult vaccines in the same doctor's visit, including 
those routinely recommended for adults age 50 years and older, such as 
influenza and pneumococcal vaccines  
• Have had a prior Zostavax > 8 weeks prior.  
2. Screen for Caution & Precautions 
Caution  
• Do not administer to anyone with an active herpes zoster outbreak  
• Do not administer to anyone who has received the live Zostavax within the last 8 
weeks  






• Moderate or severe acute illness with or without fever  
• Live vaccine, including Zostavax in the last 8 weeks  
3. Vaccine Information Statements (VIS)  
• Provide all patients with a copy of the most current federal Vaccine Information 
Statement (VIS). Provide non-English speaking patients with a copy of the VIS in 
their native language.  
4. Prepare to Administer Vaccine and refer to XX Policy: 
PP009 XX Standing Orders Med Vaccine Administration for Patients One Month and 
Older. 
PP010 XX Standing Orders Medical Management of Vaccine Reactions in Patients one 
month or Older. 
HW115 Environment of Care Proper Disposal of Sharps Needles. 
HW331 Infection Control Hand Hygiene Compliance. 
HW119 Environment of Care Medications, Specimen and Reagent Storage  
5. Administer Shingrix/Zoster Vaccine Recombinant Adjuvant  
6. Document each patient's vaccine administration information and that a VIS was provided 
in the electronic medical record.  
7. Be Prepared to Manage Medical Emergencies. 
To prevent syncope, vaccinate patients while they are seated or lying down and consider 
observing them for 15 minutes after receipt of the vaccine.  
QUALITY IMPROVEMENT:  
Standing Orders are reviewed at least annually by XX lead providers for evidence-based 
practice. 
REFERENCES: 

















Algorithm for Shingrix Curb-Side Nurse Visits 
Booking in-Vehicle Nurse Visits for Shingrix Injection 
 
 
On phone call screen patient and driver for COVID-19 
symptoms per our screening algorithm? Do they answer 




Delay book nurse visit for 
vaccine administration; 
notify provider of 
occurrence; triage if 
symptomatic person is our 
patient. 
No 
• Book nurse visit for Shingrix vaccine 
noting it will be curb side visit 
• Advise pt/family to call before visit 
with any change in health status.   
• Advise all pts need to be driven to the 
appointment by a healthy adult. 
• Advise pt/family to call the 
designated number when they 
arrive at the office parking lot.    
• Re-screen pt & driver for COVID-19. 
If no s/s use standing order to 
administer Shingrix vaccine.  If re-
screening is positive for s/s delay the 
vaccination and notify the provider if 
the symptomatic person is our 
patient. Otherwise, advise the driver 
to seek medical attention at a walk-in 
or with their PCP. 
• If both screen negative, conduct 
nurse visit as normal with PPE to 
include protective eye wear mask and 
gloves. Obtain a temperature and 
signed consent. Provide a VIS and 
have the patient wait on site for 15 
minutes following injection. 
 
